Gene therapy aims to correct genetic disorders by introducing functional genes into cells. Despite its potential, challenges such as efficient delivery, sustained expression, and immune responses remain. The first clinical trials began in 1990, but success is still elusive. Current approaches focus on somatic cells, with varying success depending on the disease and delivery method. For example, delivering a corrective gene to lung cells for cystic fibrosis is challenging, while blood-clotting disorders can be addressed by producing sufficient clotting proteins in the liver or other tissues. Gene delivery is a major hurdle, with viral and non-viral vectors being the primary methods. Viral vectors, such as retroviruses and lentiviruses, can integrate into the host genome but face issues with infecting non-dividing cells and immune responses. Lentiviruses can infect both dividing and non-dividing cells and offer sustained expression. Adenoviral vectors provide high expression but have short-term effects due to immune responses. Adeno-associated viral (AAV) vectors are non-pathogenic and can integrate into the genome, showing promise for long-term expression. Other vectors, such as herpes simplex virus and vaccinia virus, are being explored for their ability to deliver genes. Clinical trials have shown some success, such as in adenosine deaminase (ADA) deficiency, where gene therapy improved enzyme levels. However, challenges remain in achieving sustained expression and avoiding immune rejection. Future prospects involve improving vector efficiency, understanding immune responses, and developing targeted delivery systems. Advances in vector design, regulatory elements, and combining viral and non-viral systems could lead to more effective gene therapy. While challenges persist, the field shows promise, and gene therapy may become routine in the future, similar to heart transplants.Gene therapy aims to correct genetic disorders by introducing functional genes into cells. Despite its potential, challenges such as efficient delivery, sustained expression, and immune responses remain. The first clinical trials began in 1990, but success is still elusive. Current approaches focus on somatic cells, with varying success depending on the disease and delivery method. For example, delivering a corrective gene to lung cells for cystic fibrosis is challenging, while blood-clotting disorders can be addressed by producing sufficient clotting proteins in the liver or other tissues. Gene delivery is a major hurdle, with viral and non-viral vectors being the primary methods. Viral vectors, such as retroviruses and lentiviruses, can integrate into the host genome but face issues with infecting non-dividing cells and immune responses. Lentiviruses can infect both dividing and non-dividing cells and offer sustained expression. Adenoviral vectors provide high expression but have short-term effects due to immune responses. Adeno-associated viral (AAV) vectors are non-pathogenic and can integrate into the genome, showing promise for long-term expression. Other vectors, such as herpes simplex virus and vaccinia virus, are being explored for their ability to deliver genes. Clinical trials have shown some success, such as in adenosine deaminase (ADA) deficiency, where gene therapy improved enzyme levels. However, challenges remain in achieving sustained expression and avoiding immune rejection. Future prospects involve improving vector efficiency, understanding immune responses, and developing targeted delivery systems. Advances in vector design, regulatory elements, and combining viral and non-viral systems could lead to more effective gene therapy. While challenges persist, the field shows promise, and gene therapy may become routine in the future, similar to heart transplants.